Patents by Inventor Tobias Walker

Tobias Walker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230190578
    Abstract: The present invention relates to nanoparticles comprising nucleic acids coated with a (biodegradable) polymer for reversible immobilization and/or controlled release of the nucleic acid comprising nanoparticles. Furthermore, the present invention is directed to medical or diagnostic devices, particularly stents and implants coated by a (biodegradable) polymer with the nucleic acid comprising nanoparticles for reversible immobilization and/or controlled release. Furthermore, the present invention is directed to the use of these nanoparticles coated with a (biodegradable) polymer and to the use of medical devices and implants coated by the (biodegradable) polymer with these nucleic acid comprising nanoparticles in the prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of restenosis, calicification, foreign body reaction, or inflammation.
    Type: Application
    Filed: October 26, 2022
    Publication date: June 22, 2023
    Applicant: CureVac SE
    Inventors: Patrick BAUMHOF, Hans-Peter WENDEL, Andrea NOLTE, Tobias WALKER
  • Publication number: 20220249346
    Abstract: The invention relates to a polyribonucleotide, a cosmetic and pharmaceutical compound that has the polyribonucleotide and a medicinal product that has the polyribonucleotide and the compound.
    Type: Application
    Filed: October 5, 2021
    Publication date: August 11, 2022
    Applicant: Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
    Inventors: Hans-Peter WENDEL, Timea KELLER, Andrea NOLTE, Meltem AVCI-ADALI, Tobias WALKER
  • Publication number: 20170239372
    Abstract: The present invention relates to nanoparticles comprising nucleic acids coated with a (biodegradable) polymer for reversible immobilization and/or controlled release of the nucleic acid comprising nanoparticles. Furthermore, the present invention is directed to medical or diagnostic devices, particularly stents and implants coated by a (biodegradable) polymer with the nucleic acid comprising nanoparticles for reversible immobilization and/or controlled release. Furthermore, the present invention is directed to the use of these nanoparticles coated with a (biodegradable) polymer and to the use of medical devices and implants coated by the (biodegradable) polymer with these nucleic acid comprising nanoparticles in the prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of restenosis, calicification, foreign body reaction, or inflammation.
    Type: Application
    Filed: March 6, 2017
    Publication date: August 24, 2017
    Applicant: CureVac AG
    Inventors: Patrick BAUMHOF, Hans-Peter WENDEL, Andrea NOLTE, Tobias WALKER
  • Publication number: 20170042782
    Abstract: The invention relates to a polyribonucleotide, a cosmetic and pharmaceutical compound that has the polyribonucleotide and a medicinal product that has the polyribonucleotide and the compound.
    Type: Application
    Filed: September 28, 2015
    Publication date: February 16, 2017
    Applicant: Eberhard-Karls-Universitaet Tuebingen Medizinische Fakultaet
    Inventors: Hans-Peter WENDEL, Timea KELLER, Andrea NOLTE, Meltem AVCI-ADALI, Tobias WALKER
  • Publication number: 20150306249
    Abstract: The present invention relates to nanoparticles comprising nucleic acids coated with a (biodegradable) polymer for reversible immobilization and/or controlled release of the nucleic acid comprising nanoparticles. Furthermore, the present invention is directed to medical or diagnostic devices, particularly stents and implants coated by a (biodegradable) polymer with the nucleic acid comprising nanoparticles for reversible immobilization and/or controlled release. Furthermore, the present invention is directed to the use of these nanoparticles coated with a (biodegradable) polymer and to the use of medical devices and implants coated by the (biodegradable) polymer with these nucleic acid comprising nanoparticles in the prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of restenosis, calicification, foreign body reaction, or inflammation.
    Type: Application
    Filed: May 25, 2012
    Publication date: October 29, 2015
    Applicant: CureVac GmbH
    Inventors: Patrick BAUMHOF, Hans-Peter WENDEL, Andrea NOLTE, Tobias WALKER
  • Patent number: 9127281
    Abstract: The present invention relates to a nucleic acid molecule, a genetic construct, siRNA molecules and a composition which comprises the nucleic acid molecule and/or the genetic construct and/or the siRNA molecules and can be used for inhibition of the expression of endothelial adhesion molecules. The invention also relates to a device, which is coated with the aforementioned molecules, the composition or the construct, or contains them. The present invention further relates to a corresponding use of the nucleic acid molecule, of the genetic construct or of the siRNA molecules and a method of inhibition of the expression of adhesion molecules and a method of vessel grafting, lung transplantation, treatment of lung transplants, and a method of treatment of the open heart within the scope of cardioplegia.
    Type: Grant
    Filed: January 19, 2006
    Date of Patent: September 8, 2015
    Assignee: Eberhard-Karls-Universität Tübingen Universitätsklinikum
    Inventors: Tobias Walker, Hans-Peter Wendel
  • Publication number: 20080260854
    Abstract: The present invention relates to a nucleic acid molecule, a genetic construct, siRNA molecules and a composition which comprises the nucleic acid molecule and/or the genetic construct and/or the siRNA molecules and can be used for inhibition of the expression of endothelial adhesion molecules. The invention also relates to a device, which is coated with the aforementioned molecules, the composition or the construct, or contains them. The present invention further relates to a corresponding use of the nucleic acid molecule, of the genetic construct or of the siRNA molecules and a method of inhibition of the expression of adhesion molecules and a method of vessel grafting, lung transplantation, treatment of lung transplants, and a method of treatment of the open heart within the scope of cardioplegia.
    Type: Application
    Filed: January 19, 2006
    Publication date: October 23, 2008
    Inventors: Tobias Walker, Hans-Peter Wendel